Skip to content
yes i take peptides.
Library/For Skin/Melanotan I (Afamelanotide)
FDA Approved (EPP)⚠ Cancer Concern+2 more

Melanotan I (Afamelanotide)

A cyclic alpha-melanocyte-stimulating hormone analog. We read all 60 studies. The protocol is below.

Updated 03 May 2026Read 12 minEvidence ●●●●○Citations 60
+ Add to Stack
⚖ Compare side-by-side⎙ Print companion card

Free — puts Melanotan I (Afamelanotide) on your decision board.

The Melanotan I (Afamelanotide) Report · $19

Everything you need to start: dose, sourcing, safety, our verdict.

One purchase · yours forever

Built from 60 cited studies.

Status
FDA
Class
Cancer Concern
Evidence
4/ 5●●●●○
FDA approval (Scenesse, EPP)
Oct 2019
Approved indication
$19 ↓
Approved form
$19 ↓
⚠ Cancer Concern
Read this if
  • you have erythropoietic protoporphyria (EPP) and your specialist is talking about Scenesse
  • you've been running MT-II for cosmetic tan and want to understand the "FDA-approved cousin" pitch
  • you have a pale Northern-European skin type and burn before you tan
  • you ordered RUO MT-I to avoid MT-II's side-effect profile and want to know whether the vial is what the label says
Skip this if
  • you have a personal history of melanoma or atypical nevi
  • you're using it cosmetically and not under specialist supervision (Scenesse is approved as a slow-release implant for a rare disease, not as a cosmetic bolus)
  • you assume "FDA approved for one thing" means "safe for cosmetic dosing" — it doesn't (Scenesse is an intermittent supervised implant in EPP patients, not subQ injections in healthy adults)
  • you're not okay with the RUO identity problem — vials labeled MT-I frequently ship as MT-II, which is a different molecule with a different safety profile
The 4 ways you can buy Melanotan I (Afamelanotide)
Brand
✗
No FDA approval
Compounded 503A
✗
Not available
Not available (cosmetic-clinic resale ≈ $300–$800)
True 503A doesn't exist; clinic offerings are typically RUO repackaged.
RUO (research-only)
✓
Sold for research only
$50–$120/mo
Counterfeit Melanotan II often substituted for MT-I; identity verification is the recurring failure.
Gray market
✓
Illegal to import for huma…
$7–$10/mo at 10mg/mo
Small relative to MT-II gray market; same MC1R/melanoma concerns apply.
Click any lane for the full Sourcing breakdown.
First 90 days · Melanotan I (Afamelanotide)
Weeks 1–2
Tolerability check. Mild contact irritation or transient redness is normal for the first 1–2 weeks. Stop and patch-test if you get persistent dermatitis.
Weeks 4–8
Texture changes if it's going to work. Take a baseline photo at week 0 — week 8 vs baseline is the honest comparator. Your memory of how your skin looked is unreliable.
Week 12 — decide
Side-by-side photo decision. Cosmetic peptide effects are slow and modest. Anyone promising fast dramatic results is selling marketing, not skin biology.
Quit if
  • Persistent contact dermatitis or worsening irritation.
  • No perceived change in week 8 and week 12 photo comparisons (cosmetic peptides usually take longer than 12 weeks, but at 16 weeks if nothing has changed, the formulation isn't reaching the target).
  • Any pigmentation changes that persist after stopping.
Identity

What it is.

Melanotan I is afamelanotide — a 13-amino-acid synthetic analog of alpha-MSH, more selective for the melanocortin-1 receptor than its messier sibling MT-II. It binds the tanning receptor, mostly leaves the libido and appetite receptors alone, and triggers melanin production with a cleaner side-effect profile.

It's the version that finished the regulatory pipeline. Marketed as Scenesse by Clinuvel, it was approved by the EMA in 2014 and the FDA in 2019 for adults with erythropoietic protoporphyria (EPP) — a rare genetic light-sensitivity disorder where sunlight causes severe pain. By increasing baseline melanin, afamelanotide reduces phototoxic episodes.

It's delivered as a subcutaneous implant in the EPP setting, every two months, in a clinic. The off-label tanning market also uses injectable vials of the same molecule sold . Same compound, different supply chain.

TL;DR

TL;DR. 30-second version.

The compressed verdict — what Melanotan I (Afamelanotide) actually is, what the human evidence shows, and the watch-for in three bullets. Locked.

Get the report · $19 ↓
Mechanism

Mechanism.

Mechanism · in the Melanotan I (Afamelanotide) report

How the molecule actually works — receptor profile, downstream signaling, what to expect mechanistically.

Get the report · $19 ↓
Evidence

Evidence. What we actually know in humans.

Evidence · in the Melanotan I (Afamelanotide) report

The trial breakdown — phase, n, primary endpoint, who funded, what hit, what didn't.

Get the report · $19 ↓
Human-Evidence Factbox
FDA approval (Scenesse, EPP)
Oct 2019
Approved indication
$19 ↓
Approved form
$19 ↓
Approved population
$19 ↓
Phase 3 trials
$19 ↓
Cosmetic subQ-bolus use validated
$19 ↓
RUO MT-I commonly ships as
$19 ↓
Long-term melanoma risk
$19 ↓
Off-label market size
$19 ↓
Dose

Dose. The actual protocol.

Dose · in the Melanotan I (Afamelanotide) report

The specific protocol — dose, titration schedule, cycle pattern, frequency, route.

We read 60 studies to write this report.
Get the report · $19 ↓
Sourcing

Sourcing. Where the cohort actually buys.

Sourcing · in the Melanotan I (Afamelanotide) report

Sourcing breakdown — vendor methodology, red flags, our published test results, COA checklist.

We read 60 studies to write this report.
Get the report · $19 ↓
Safety

Safety. Side effects.

Safety · in the Melanotan I (Afamelanotide) report

The watch-for list — contraindications, drug interactions, monitoring labs, when to stop.

Get the report · $19 ↓
Editorial Position

Editorial position.

Editorial Position · in the Melanotan I (Afamelanotide) report

Our editorial position — explicit yes / no / depends, with the reasoning behind it.

Get the report · $19 ↓
Citations

Citations.

  1. 01Perez-Bootello J, et al. Vitiligo: Pathogenesis and New and Emerging Treatments. International journal of molecular sciences. 2023;24(24). PMID: 38139134.
  2. 02Diotallevi F, et al. Vitiligo, from Pathogenesis to Therapeutic Advances: State of the Art. International journal of molecular sciences. 2023;24(5). PMID: 36902341.
  3. 03— Afamelanotide. 2024. PMID: 38598652.
  4. 04Iwanowski T, et al. Etiopathogenesis and Emerging Methods for Treatment of Vitiligo. International journal of molecular sciences. 2023;24(11). PMID: 37298700.
  5. 05Cong TX, et al. From pathogenesis of acne vulgaris to anti-acne agents. Archives of dermatological research. 2019;311(5):337-349. PMID: 30859308.
+Show all 60 citations
  1. 06Ismail IB, et al. Treatment Advances in Vitiligo: An Updated Review. Dermatology practical & conceptual. 2025;15(1). PMID: 40117616.
  2. 07Zubair R, et al. Phototherapy for Vitiligo. Dermatologic clinics. 2020;38(1):55-62. PMID: 31753192.
  3. 08Balwani M, et al. X-Linked Protoporphyria. 2019. PMID: 23409301.
  4. 09Polańska A, et al. Afamelanotide in protoporphyria and other skin diseases: a review. Postepy dermatologii i alergologii. 2024;41(2):149-154. PMID: 38784937.
  5. 10Stölzel U, et al. [Porphyrias-what is verified?]. Der Internist. 2018;59(12):1239-1248. PMID: 30328490.
  6. 11Wensink D, et al. Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert review of clinical pharmacology. 2021;14(2):151-160. PMID: 33507118.
  7. 12Kim ES, et al. Afamelanotide: A Review in Erythropoietic Protoporphyria. American journal of clinical dermatology. 2016;17(2):179-85. PMID: 26979527.
  8. 13Minder EI, et al. Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. Clinical pharmacokinetics. 2017;56(8):815-823. PMID: 28063031.
  9. 14Sweeney P, et al. Targeting the central melanocortin system for the treatment of metabolic disorders. Nature reviews. Endocrinology. 2023;19(9):507-519. PMID: 37365323.
  10. 15Langendonk JG, et al. Afamelanotide for Erythropoietic Protoporphyria. The New England journal of medicine. 2015;373(1):48-59. PMID: 26132941.
  11. 16Wu J, et al. Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications. Journal of drugs in dermatology : JDD. 2021;20(3):290-294. PMID: 33683075.
  12. 17Kluijver LG, et al. The effects of cholecalciferol and afamelanotide on vitamin D levels in erythropoietic protoporphyria: a multicentre cohort study. The British journal of dermatology. 2024;191(3):357-364. PMID: 38634774.
  13. 18Searle T, et al. Systemic photoprotection in 2021. Clinical and experimental dermatology. 2021;46(7):1189-1204. PMID: 33872410.
  14. 19Minder AE, et al. Erythropoietic protoporphyrias: Pathogenesis, diagnosis and management. Liver international : official journal of the International Association for the Study of the Liver. 2025;45(1):e16027. PMID: 39011756.
  15. 20Minder EI. Afamelanotide, an agonistic analog of α-melanocyte-stimulating hormone, in dermal phototoxicity of erythropoietic protoporphyria. Expert opinion on investigational drugs. 2010;19(12):1591-602. PMID: 21073357.
  16. 21Balwani M, et al. Erythropoietic Protoporphyria, Autosomal Recessive. 2017. PMID: 23016163.
  17. 22Minder EI, et al. Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria. Expert review of clinical pharmacology. 2015;8(1):43-53. PMID: 25470471.
  18. 23Zubair R, et al. What's New in Pigmentary Disorders. Dermatologic clinics. 2019;37(2):175-181. PMID: 30850040.
  19. 24Farahnik B, et al. Interventional treatments for Hailey-Hailey disease. Journal of the American Academy of Dermatology. 2017;76(3):551-558.e3. PMID: 27745906.
  20. 25Lane AM, et al. Advances in the management of erythropoietic protoporphyria - role of afamelanotide. The application of clinical genetics. 2016;9:179-189. PMID: 28003770.
  21. 26Biolcati G, et al. Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease. Clinical and experimental dermatology. 2014;39(2):168-75. PMID: 24256215.
  22. 27Minder AE, et al. Afamelanotide Is Associated with Dose-Dependent Protective Effect from Liver Damage Related to Erythropoietic Protoporphyria. Life (Basel, Switzerland). 2023;13(4). PMID: 37109595.
  23. 28Rhodes LE. Vitamin D status in patients with erythropoietic protoporphyria taking the systemic photoprotective agent afamelanotide. The British journal of dermatology. 2024;191(3):317-318. PMID: 38736212.
  24. 29Dawe R. An overview of the cutaneous porphyrias. F1000Research. 2017;6:1906. PMID: 29152226.
  25. 30Leaf RK, et al. Afamelanotide for Treatment of the Protoporphyrias: Impact on Quality of Life and Laboratory Parameters in a US Cohort. Life (Basel, Switzerland). 2024;14(6). PMID: 38929673.
  26. 31Luger TA, et al. An α-MSH analog in erythropoietic protoporphyria. The Journal of investigative dermatology. 2015;135(4):929-931. PMID: 25785940.
  27. 32Resnik SR, et al. Into the Light: Afamelanotide and the Treatment of Erythropoietic Protoporphyria in the United States. Journal of drugs in dermatology : JDD. 2023;22(9):941-949. PMID: 37683058.
  28. 33Wensink D, et al. Objective light exposure measurements and circadian rhythm in patients with erythropoietic protoporphyria: A case-control study. Molecular genetics and metabolism. 2022;135(3):215-220. PMID: 35034844.
  29. 34Habbema L, et al. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. International journal of dermatology. 2017;56(10):975-980. PMID: 28266027.
  30. 35Passeron T. Medical and Maintenance Treatments for Vitiligo. Dermatologic clinics. 2017;35(2):163-170. PMID: 28317526.
  31. 36Searle T, et al. Vitiligo: an update on systemic treatments. Clinical and experimental dermatology. 2021;46(2):248-258. PMID: 33350506.
  32. 37Rodrigues M, et al. Current and emerging treatments for vitiligo. Journal of the American Academy of Dermatology. 2017;77(1):17-29. PMID: 28619557.
  33. 38Chang CL, et al. A gel-forming α-MSH analog promotes lasting melanogenesis. European journal of pharmacology. 2023;958:176008. PMID: 37673364.
  34. 39Jafarzadeh A, et al. A systematic review of case series and clinical trials investigating systemic oral or injectable therapies for the treatment of vitiligo. Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI). 2024;30(3):e13642. PMID: 38454597.
  35. 40Lim HW, et al. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA dermatology. 2015;151(1):42-50. PMID: 25230094.
  36. 41Fabrikant J, et al. A review and update on melanocyte stimulating hormone therapy: afamelanotide. Journal of drugs in dermatology : JDD. 2013;12(7):775-9. PMID: 23884489.
  37. 42de Baat C, et al. [Medicaments and oral healthcare. Hyperpigmentation of oral soft tissues due to afamelanotide]. Nederlands tijdschrift voor tandheelkunde. 2020;127(4):237-243. PMID: 32459219.
  38. 43Kluijver LG, et al. The Impact of Minimal Sunlight Exposure on Bone Health: Insights From a Cohort Study in Erythropoietic Protoporphyria. The Journal of clinical endocrinology and metabolism. 2025;110(6):1633-1646. PMID: 39401412.
  39. 44Homey B, et al. German Cohort Observational Study to Investigate the Short- and Long-Term Safety and Clinical Effectiveness of Afamelanotide 16 mg (SCENESSE) in Patients With Erythropoietic Protoporphyria (EPP). Photodermatology, photoimmunology & photomedicine. 2025;41(2):e13012. PMID: 40082741.
  40. 45Nkwanyana N, et al. Silica-Assisted Solid-Phase Peptide Synthesis (SiPPS). Journal of peptide science : an official publication of the European Peptide Society. 2025;31(9):e70052. PMID: 40817749.
  41. 46Wensink D, et al. Association of Afamelanotide With Improved Outcomes in Patients With Erythropoietic Protoporphyria in Clinical Practice. JAMA dermatology. 2020;156(5):570-575. PMID: 32186677.
  42. 47Toenne M, et al. Erythropoietic protoporphyria in childhood: clinical clues, missed diagnoses and emerging therapy. European journal of pediatrics. 2025;184(9):580. PMID: 40858983.
  43. 48Minder AE, et al. Beyond pigmentation: signs of liver protection during afamelanotide treatment in Swiss patients with erythropoietic protoporphyria, an observational study. Therapeutic advances in rare disease. 2021;2:26330040211065453. PMID: 37181106.
  44. 49Lim HW, et al. Current challenges in photoprotection. Journal of the American Academy of Dermatology. 2017;76(3S1):S91-S99. PMID: 28038886.
  45. 50Bardhan M, et al. Polymorphism of Melanocortin Receptor Genes-Association with Inflammatory Traits and Diseases. Diseases (Basel, Switzerland). 2025;13(9). PMID: 41002740.
  46. 51Lengweiler S, et al. Evaluation of the immunogenicity of the synthetic α-melanocyte-stimulating hormone (α-MSH) analogue afamelanotide ([Nle4-D-Phe7]-α-MSH, Scenesse®) in erythropoietic protoporphyria patients by ELISA detecting both anti-afamelanotide and anti-α-MSH antibodies. Skin pharmacology and physiology. 2015;28(2):103-13. PMID: 25402764.
  47. 52Wensink D, et al. Erythropoietic protoporphyria in the Netherlands: Clinical features, psychosocial impact and the effect of afamelanotide. The Journal of dermatology. 2023;50(4):445-452. PMID: 36579412.
  48. 53O'Reilly M, et al. Erythropoietic protoporphyria and afamelanotide: a patient's perspective. Clinical and experimental dermatology. 2024;49(2):186-187. PMID: 37831089.
  49. 54Al Shaer D, et al. 2019 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals (Basel, Switzerland). 2020;13(3). PMID: 32151051.
  50. 55Biolcati G, et al. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. The British journal of dermatology. 2015;172(6):1601-1612. PMID: 25494545.
  51. 56Erwin AL, et al. Porphyrias in the Age of Targeted Therapies. Diagnostics (Basel, Switzerland). 2021;11(10). PMID: 34679493.
  52. 57Spichty R, et al. A bioassay for the detection of neutralizing antibodies against the α-melanocyte stimulating hormone analog afamelanotide in patients with erythropoietic protoporphyria. Journal of pharmaceutical and biomedical analysis. 2013;75:192-8. PMID: 23277150.
  53. 58Karagaiah P, et al. Emerging drugs for the treatment of vitiligo. Expert opinion on emerging drugs. 2020;25(1):7-24. PMID: 31958256.
  54. 59Stanislaus V, et al. A feasibility and safety study of afamelanotide in acute stroke patients - an open label, proof of concept, phase iia clinical trial. BMC neurology. 2023;23(1):281. PMID: 37496004.
  55. 60Fontanellas A, et al. Current and innovative emerging therapies for porphyrias with hepatic involvement. Journal of hepatology. 2019;71(2):422-433. PMID: 31102718.
The Melanotan I (Afamelanotide) Report · $19

Everything you need to start.

Dose, sourcing, safety, our verdict. One purchase. Yours forever.

Built from 60 cited studies.

Or get every report. All reports — $99 once · Pro — $29/mo.
Compare tiers →